Status:
COMPLETED
Study of XL820 in Adults With Solid Tumors
Lead Sponsor:
Exelixis
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.
Eligibility Criteria
Inclusion
- Advanced solid tumor
- Cancer for which standard therapies do not exist or are no longer effective
- Life expectancy of \> 3 months
- Adequate bone marrow, liver, and kidney function
- Willing to use accepted method of contraception during the course of the study
- Negative pregnancy test (females)
- Written informed consent
Exclusion
- Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
- Investigational drug within 30 days of the start of treatment
- Subjects with known brain metastasis
- Uncontrolled medical disorder such as infection or cardiovascular disease
- Subjects known to be HIV positive
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00129571
Start Date
August 1 2005
Last Update
June 4 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
2
Cancer Therapy and Research Center
San Antonio, Texas, United States, 78229